@ChildrenNeedUs_@adamfeuerstein She mentioned it later: even though they had set exclusion criteria they still ended up with quite a few patients from the excluded groups
@MaverickNY@adamfeuerstein@matthewherper Let’s have a thought experiment: assume that the key future for these bispex is trop-2 ADC combination - so who is the best partner for ivonescimab given what we have seen from sacTMT vs Trodelvy vs Datroway?
@pemulisking@matthewherper@avidresearch@adamfeuerstein We are all trying to find holes in it, which natural. But all caveats aside, this good as it opens the door for combo studies. Even if the ex-China data is weaker at 0.76 for example, that’s still good for a first generation.
@daphnezohar@jrkelly Couldn’t have said it better. I am serious when I say we may need a group formed by impartial industry focused patient-centric executive to deliver a coherent message about the real problems. Are BIO and PhRMA delivering these?
@daphnezohar@jrkelly So much energy is being spent on this topic whilst all we need to do is double down on science funding and keep the brilliant brains behind US biotech in the US, wherever they come from.